

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
28th October 2024

Company: Chordia Therapeutics, Inc
Representative: Chief Executive Officer Hiroshi Miyake
(Security Code: 190A TSE Growth Market)
Contact: Chief Financial Officer Kentaro Kume

Chordia announces the Release of a Transcript of the Earnings Briefing for the Fiscal Year Ended August 2024

Kanagawa Japan

28th October 2024 – Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; President: Hiroshi Miyake) held a “Financial Results Briefing for the Period Ending August 2024” on Tuesday, October 15, 2024, and the transcript of the event (including the Q&A session) has been published on our website.

We believe that this will help to bridge the information gap between investors and the company and lead to a deeper understanding of our business, and we will continue to strive for fair information disclosure.

1. Overview

Date : Tuesday, October 15, 2024, 15:30 - 16:30 (JST)
Presenter : Hiroshi Miyake, Chief Executive Officer
Method of holding : Web-based

2. Transcript article URL

<https://www.chorditherapeutics.com/en/ir/library/result.html>

About Chordia Therapeutics

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers.

Chordia’s lead asset, CLK inhibitor CTX-712, is under Phase 1/2 clinical study in the US. CTX-712 potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to CTX-712, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors. For more information, please contact our website <https://www.chorditherapeutics.com/en/>.